Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma).

Trial Profile

Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma).

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 18 Feb 2017 Results assessing the safety and efficacy of sorafenib in elderly patients (n=772) presented at the 2017 Genitourinary Cancers Symposium
    • 11 Apr 2012 Actual patient number (3304) added as reported by ClinicalTrials.gov.
    • 11 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top